Literature DB >> 8032339

When and how does one search for inborn errors of purine and pyrimidine metabolism?

H A Simmonds1.   

Abstract

Disorders in purine and pyrimidine metabolism may be difficult to recognize because their recent description means many are little known. They cover a broad spectrum of illnesses, can present from birth to the 80s, have multiple symptoms and lead to early death. Recognition of new disorders requires skill and serendipity. Often parents of affected children provide valuable clues. These disorders should be suspected, particularly where the history involves siblings, in anaemia, susceptibility to infection, or neurological deficits including autism, delayed development, epilepsy, self-mutilation, muscle weakness and - unusual in children and adolescents - gout. Some patients present with kidney stones, renal failure, alone or with the above, or as an intolerance/sensitivity to therapy (fluorouracil or azathioprine immunosuppression). These disorders can be detected from the abnormal metabolites in body fluids and/or altered enzyme activity. Abnormal cellular nucleotides or renal clearance may sometimes provide the only clue. Diagnosis can be difficult because of genetic heterogeneity and interference by blood transfusion, diet or drugs. Tests incorporating enzyme peak shifts and online diode-array detection are essential. Collaborative research is needed to improve the diagnosis and understanding of the metabolic basis for these sometimes devastating disorders and to apply this knowledge to the more common killers of mankind.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8032339     DOI: 10.1007/bf01880664

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  23 in total

1.  Distinct neurological syndrome in two brothers with hyperuricaemia.

Authors:  H J Christen; F Hanefeld; J A Duley; H A Simmonds
Journal:  Lancet       Date:  1992-11-07       Impact factor: 79.321

2.  Erythrocyte nucleotide stability and plasma hypoxanthine concentrations: improved ATP stability with short-term storage at room temperature.

Authors:  H A Simmonds; V Micheli; P M Davies; M B McBride
Journal:  Clin Chim Acta       Date:  1990-11-30       Impact factor: 3.786

3.  [Hypouricemia--a differential diagnostic problem].

Authors:  G Hillebrand; S Reiter
Journal:  Internist (Berl)       Date:  1991-04       Impact factor: 0.743

4.  Urate and p-aminohippurate transport in the brush border membrane of the pig kidney.

Authors:  D Werner; F Martinez; F Roch-Ramel
Journal:  J Pharmacol Exp Ther       Date:  1990-02       Impact factor: 4.030

5.  The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients.

Authors:  P R Chocair; J A Duley; H A Simmonds; J S Cameron
Journal:  Transplantation       Date:  1992-05       Impact factor: 4.939

6.  Selective accumulation of cytosol CDP-choline as an isolated erythrocyte defect in chronic hemolysis.

Authors:  D E Paglia; W N Valentine; M Nakatani; B J Rauth
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

7.  Altered erythrocyte nucleotide patterns are characteristic of inherited disorders of purine or pyrimidine metabolism.

Authors:  H A Simmonds; L D Fairbanks; G S Morris; D R Webster; E H Harley
Journal:  Clin Chim Acta       Date:  1988-02-15       Impact factor: 3.786

Review 8.  Purine nucleoside phosphorylase deficiency.

Authors:  M L Markert
Journal:  Immunodefic Rev       Date:  1991

Review 9.  Gout, uric acid and purine metabolism in paediatric nephrology.

Authors:  J S Cameron; F Moro; H A Simmonds
Journal:  Pediatr Nephrol       Date:  1993-02       Impact factor: 3.714

10.  A mutation in adenylosuccinate lyase associated with mental retardation and autistic features.

Authors:  R L Stone; J Aimi; B A Barshop; J Jaeken; G Van den Berghe; H Zalkin; J E Dixon
Journal:  Nat Genet       Date:  1992-04       Impact factor: 38.330

View more
  1 in total

Review 1.  Inborn errors of purine and pyrimidine metabolism.

Authors:  A Jurecka
Journal:  J Inherit Metab Dis       Date:  2009-03-15       Impact factor: 4.982

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.